Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer receives Welsh recommendation for Xiapex

Pfizer receives Welsh recommendation for Xiapex

16th January 2012

Pfizer has received a recommendation from the All Wales Medicine Strategy Group for its Dupuytren's contracture therapy Xiapex to be used among NHS patients.

The organisation has endorsed the use of the therapy as a means of treating adult Dupuytren's contracture patients with a palpable cord, making it the first UK health technology body to offer an approval for the collagenase clostridium histolyticum treatment.

Xiapex is designed to provide an alternative to surgery among patients suffering from the condition, which causes excessive collagen production within the hands and can lead to physical disability.

Many are reluctant to undergo surgery due to the downtime this can involve, thus making Xiapex potentially beneficial to Welsh patients.

Henry Orton, co-founder of the British Dupuytren's Society, said: "Collagenase clostridium histolyticum is a welcome and long-awaited alternative to surgery in the treatment of Dupuytren's contracture."

This comes after the company's promising new rheumatoid arthritis drug tofacitinib was recently accepted for regulatory review by the European Medicines Agency.ADNFCR-8000103-ID-801265090-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.